Murchinson’s Vanda Pharmaceuticals VNDA Stock Holding History

Murchinson’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$207K	–	157
2026 Q1	$207K	Buy	+30,000	New	+$231K	0.03%	90

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Murchinson's VNDA Position: Q2 2026 in Review

Murchinson sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 30,000 shares — an estimated $207K sold.

Murchinson first reported a position in VNDA in Q1 2026 and held it in 1 quarter. The position peaked at $207K in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Murchinson reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Murchinson sold 30,000 Vanda Pharmaceuticals shares in Q2 2026, an estimated $207K.
Murchinson first reported a position in Vanda Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Murchinson's Vanda Pharmaceuticals position peaked at $207K in Q1 2026.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Murchinson's 13F filing for Q2 2026, filed 14 Aug 2026.